Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer.
Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer.
复制标题
DOI：
10.3802/jgo.2014.25.1.58
复制
发表时间：
2014-01
影响因子：
3.9
通讯作者：
Mizunuma H
中科院分区：
文献类型：
--
作者：
Yokoyama Y;Matsushita Y;Shigeto T;Futagami M;Mizunuma H
ARID1A 的缺失与卵巢透明细胞腺癌的致癌转化有关。本研究在所有组织类型的上皮性卵巢癌中进行，以探讨 ARID1A 表达水平的增加或减少是否可以成为卵巢癌的预后因素或是否可以影响抗癌药物的敏感性。研究人员对 2006 年至 2011 年间在弘前大学医院接受初始治疗的 111 名上皮性卵巢癌患者中的 ARID1A 表达水平进行了调查。 ARID1A 的表达水平使用染色评分进行免疫组织化学分级，染色评分是通过将细胞核的染色强度乘以染色阳性面积来计算的。透明细胞腺癌中 ARID1A 的水平显着低于其他组织学类型。在 III、IV 期癌症患者 (n=46) 中，未达到完全缓解 (CR；n=12) 的患者 ARID1A 水平显着低于达到 CR 的患者 (n=34) (p=0.026)。达到 CR 后复发的患者 (n=21) 的 ARID1A 水平相对较低 (p=0.07)，而未复发的患者 (n=13) 则相对较低。当染色评分为0被定义为ARID1A阴性，其他染色评分被定义为ARID1A阳性时，III、IV期疾病的ARID1A阴性（n = 11）和ARID1A阳性（n = 35）患者的无进展生存期存在显着差异。结果表明，ARID1A 表达减少与化疗耐药相关，并且可能是达到 CR 后晚期癌症复发风险的预测因素。
Loss of ARID1A is related to oncogenic transformation of ovarian clear cell adenocarcinoma. The present study was conducted in epithelial ovarian cancer of all tissue types to investigate whether an increased or decreased expression level of ARID1A can be a prognostic factor for ovarian cancer or can influence the sensitivity to anticancer drugs. The expression level of ARID1A was investigated in 111 patients with epithelial ovarian cancer who received initial treatment at the Hirosaki University Hospital between 2006 and 2011. The expression level of ARID1A was immunohistochemically graded using staining scores, which were calculated by multiplying the staining intensity of the nuclei by the stain-positive area. The level of ARID1A was significantly lower in clear cell adenocarcinoma than in other histologic types. Among the patients with stage III, IV cancer (n=46), the level of ARID1A was significantly lower (p=0.026) in patients who did not achieve complete response (CR; n=12) than in patients who achieved CR (n=34). The level of ARID1A was relatively lower (p=0.07) in patients who relapsed after achieving CR (n=21) than in patients who did not relapse (n=13). When the staining score of 0 was defined as ARID1A-negative and other staining scores were defined as ARID1A-positive, there was significant difference in progression-free survival between ARID1A-negative (n=11) and ARID1A-positive (n=35) patients in stage III, IV disease. The result suggests that decreased ARID1A expression is correlated with chemoresistance and may be a predictive factor for the risk of relapse of advanced cancer after achieving CR.
登录
查看更多内容
影响因子：
7.5
作者：
Samartzis, Eleftherios P.;Samartzis, Nicolas;Imesch, Patrick
通讯作者：
Imesch, Patrick
影响因子：
7.3
作者：
Wiegand, Kimberly C.;Lee, Anna F.;Huntsman, David G.
通讯作者：
Huntsman, David G.
影响因子：
158.5
作者：
Burger, Robert A.;Brady, Mark F.;Liang, Sharon X.
通讯作者：
Liang, Sharon X.
DOI：
10.1097/igc.0b013e31826b5dcc
发表时间：
2012-10
期刊：
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
影响因子：
--
作者：
Ayhan A;Mao TL;Seckin T;Wu CH;Guan B;Ogawa H;Futagami M;Mizukami H;Yokoyama Y;Kurman RJ;Shih IeM
通讯作者：
Shih IeM
DOI：
10.1126/science.1196333
发表时间：
2010-10-08
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Jones S;Wang TL;Shih IeM;Mao TL;Nakayama K;Roden R;Glas R;Slamon D;Diaz LA Jr;Vogelstein B;Kinzler KW;Velculescu VE;Papadopoulos N
通讯作者：
Papadopoulos N